Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:INNT

Innovate Biopharmaceuticals (INNT) Stock Price, News & Analysis

Innovate Biopharmaceuticals logo

About Innovate Biopharmaceuticals Stock (NASDAQ:INNT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.56
$1.42
52-Week Range
N/A
Volume
25 shs
Average Volume
525,982 shs
Market Capitalization
$8 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive INNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Innovate Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INNT Stock News Headlines

Presidential Bombshell: $150T Resource to Be Released as soon as this Summer?
Something extraordinary is happening in Washington. For the first time in over a century, a sitting President could release a national treasure that's been tied up in red tape, for generations. I'm talking about a $150 trillion American asset that's scattered across all 50 states. While the mainstream media focuses on political theater, this story is quietly developing behind closed doors.
See More Headlines

INNT Stock Analysis - Frequently Asked Questions

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) announced its earnings results on Monday, March, 18th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11).

Based on aggregate information from My MarketBeat watchlists, some other companies that Innovate Biopharmaceuticals investors own include 9 Meters Biopharma (NMTR), NIO (NIO), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET), Iterum Therapeutics (ITRM), Meta Platforms (META) and Micron Technology (MU).

Company Calendar

Last Earnings
3/18/2019
Today
7/07/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INNT
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.05 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.27) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$8 thousand
Optionable
Not Optionable
Beta
-0.39
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:INNT) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners